Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

被引：2
|
作者：
Lemelin, A. [1 ]
Takemura, K. [2 ]
Boyne, D. J. [3 ]
Warkentin, M. T. [3 ]
Brenner, D. R. [3 ]
Cheun, W. Y. [3 ,6 ]
Wells, J. C. [4 ]
Labaki, C.
McGregor, B. A. [6 ]
Basappa, N. S. [7 ]
Meza, L. A. [8 ]
Pal, S. K. [8 ]
Beuselinck, B. [9 ]
Mckay, R. R. [10 ]
Szabados, B. E. [11 ]
Powles, T. B. [12 ]
Yuasa, T. [13 ]
Ludwig, L. [14 ]
Choueiri, T. K. [5 ]
Heng, D. Y. C. [2 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Oncol Dept, Calgary, AB, Canada
[3] Univ Calgary, Oncol Dept, Oncol, Calgary, AB, Canada
[4] BC Canc Agcy, Oncol, Vancouver, BC, Canada
[5] Dana Farber Canc Inst, Med Genet Unit, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Cross Canc Inst, Med Oncol Dept, Edmonton, AB, Canada
[8] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[9] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[10] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[11] Barts & London Queen Marys Sch Med & Dent, Med Oncol Dept, Canc Res UK Barts Ctr, London, England
[12] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England
[13] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[14] Ipsen Biopharmaceut Canada Inc, Med Sci Liaison, Mississauga, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1902P
引用
收藏
页码：S1023 / S1024
页数：2
相关论文
共 50 条
  • [1] Real world outcomes of first line (1L) nivolumab and ipilimumab (NIVO IPI) in metastatic renal cell carcinoma (mRCC): An update from the International mRCC Database Consortium (IMDC).
    Ferrier, Evan
    Lemelin, Audreylie
    Powles, Thomas
    Pal, Sumanta Kumar
    Ebrahimi, Hedyeh
    Agarwal, Neeraj
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Wood, Lori
    Canil, Christina M.
    Saliby, Renee Maria
    de Velasco, Guillermo
    Mckay, Rana R.
    Tran, Ben
    Suarez, Cristina
    Templeton, Arnoud J.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 395 - 395
  • [2] Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Wells, J. Connor
    Schmidt, Andrew Lachlan
    Powles, Thomas
    Tran, Ben
    Meza, Luis A.
    Labaki, Chris
    Lee, Jae-Lyun
    Wood, Lori
    Shapiro, Julia
    Ernst, D. Scott
    Kapoor, Anil
    Canil, Christina M.
    Yuasa, Takeshi
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Dudani, Shaan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [4] Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).
    Lemelin, Audreylie
    Takemura, Kosuke
    Ernst, Matthew Scott
    Wells, J. Connor
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Davis, Ian D.
    Wood, Lori
    Pal, Sumanta Kumar
    Hansen, Aaron Richard
    Kollmannsberger, Christian K.
    Bjarnason, Georg A.
    Tran, Ben
    Li, Haoran
    Kanesvaran, Ravindran
    Powles, Thomas
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John A.
    McGregor, Bradley Alexander
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Zanotti, Giovanni
    Huynh, Lynn
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Real-world assessment of clinical outcomes among first-line (1 L) Sunitinib patients with metastatic renal cell carcinoma (MRCC) by the international Mrcc database consortium (IMDC) risk group
    Lynn Huynh
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John
    McGregor, Bradley
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Hansen, Aaron
    Iafolla, Marco
    Zanotti, Giovanni
    Nguyen, Catherine
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 124 - 125
  • [7] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
    Geynisman, Daniel M.
    Faccone, Jillian
    Zhang Ying
    Ejzykowicz, Flavia
    Stwalley, Brian
    Hamilton, Melissa
    Le, Trong Kim
    Huo, Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [10] Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor
    Donskov, Frede
    Pal, Sumanta K.
    Dizman, Nazli
    Rathi, Nityam
    Beuselinck, Benoit
    Yan, Flora
    Lalani, Aly-Khan A.
    Hansen, Aaron Richard
    Szabados, Bernadett
    de Velasco, Guillermo
    Tran, Ben
    Lee, Jae-Lyun
    Vaishampayan, Ulka N.
    Bjarnason, Georg A.
    Subasri, Mathushan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345